|
Risk of solid cancer after treatment for testicular germ cell cancer in the platinum era. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi |
Research Funding - Bayer (Inst); Sanofi (Inst) |
| |
|
Consulting or Advisory Role - BioCancell; Cepheid; MEL Pharma; Nucleix; Spectrum Pharmaceuticals; taris |
Research Funding - cepheid (Inst); Nucleix (Inst); taris (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Astellas Pharma (Inst) |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Ipsen (Inst); Pfizer (Inst) |
| |
Alfonsus Johannes Maria van den Eertwegh |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Ipsen; MSD Oncology; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Roche; Sanofi |
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Alphonsus C.M. Van Den Bergh |
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Abbvie (Inst); Roche/Genentech (Inst); Siemens (Inst) |
| |
|
No Relationships to Disclose |